BioLine Rx (XTAE:BLRX) Debt-to-EBITDA : -0.21 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is BioLine Rx Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

BioLine Rx's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₪14.06 Mil. BioLine Rx's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₪30.31 Mil. BioLine Rx's annualized EBITDA for the quarter that ended in Dec. 2023 was ₪-216.42 Mil. BioLine Rx's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.20.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for BioLine Rx's Debt-to-EBITDA or its related term are showing as below:

XTAE:BLRX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.55 Med: -0.2 Max: -0.01
Current: -0.2

During the past 13 years, the highest Debt-to-EBITDA Ratio of BioLine Rx was -0.01. The lowest was -0.55. And the median was -0.20.

XTAE:BLRX's Debt-to-EBITDA is ranked worse than
100% of 278 companies
in the Biotechnology industry
Industry Median: 1.375 vs XTAE:BLRX: -0.20

BioLine Rx Debt-to-EBITDA Historical Data

The historical data trend for BioLine Rx's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Debt-to-EBITDA Chart

BioLine Rx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.47

-0.28

-0.18

-0.55

-0.20

BioLine Rx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.67	-0.29	-0.20	-0.22	-0.21

Competitive Comparison of BioLine Rx's Debt-to-EBITDA

For the Biotechnology subindustry, BioLine Rx's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLine Rx's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Debt-to-EBITDA falls into.

BioLine Rx Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

BioLine Rx's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(14.058	+	30.306)	/	-218.498
	=	-0.20

BioLine Rx's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(14.058	+	30.306)	/	-216.42
	=	-0.20

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

BioLine Rx (XTAE:BLRX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

BioLine Rx Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLine Rx (XTAE:BLRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (XTAE:BLRX) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

BLRX:USA YP2A:Germany

Address

2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website

https://www.biolinerx.com

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.